Abstract: Nanoparticle-based drug delivery is an emerging technology for targeting therapeutics to the diseased site for enhanced therapy and reduced toxicity. A number of pharmaceutical products that involve nanotechnology have been approved for clinical use, and because of altered pharmacokinetics and biodistribution, their profiles of interaction with host cells and resulting toxicity are different from parent agents. This review focuses on the immune responses induced by therapeutic lipid nanoparticles. These immune responses can provoke toxicity, affect pharmacokinetics of the nanoparticles or induce therapeutic effect. This article begins with a general introduction on immune responses and innate and acquired immunity. Specific examples of therapeutic lipid nanoparticles inducing immune responses in each category are presented with detailed discussions on the mechanisms. Current guidelines for evaluating immune response of nanomedicines are summarized. Finally, perspectives and future directions are provided emphasizing mechanistic studies of immune reactions triggered by nanoparticles.
Introduction
Nanotechnology has been utilized to provide enhanced imaging contrast and to improve solubility, pharmacokinetics and targeted delivery of therapeutic molecules. More than 200 nano-enabled products have entered pharmaceutical pipelines [1] , and a number of them have been approved by the US Food and Drug Administration (FDA), 
and iron oxide nanoparticles (Feridex ® ). These products often exhibit distinguished pharmacokinetics and biodistribution compared to their parent compounds, resulting in different toxicology profiles. For example, Doxil displays reduced cardiac uptake of doxorubicin and enhanced accumulation in the skin, leading to decreased cardiotoxicity and increased incidence of mucositis [2] . As a result, the dose limiting toxicity of Doxil is hand and foot syndrome, instead of heart damage [2] . Therefore, toxicology of nanomedicine is one of the major research topics in the field and all nano-products need to go through rigorous toxicology studies before regulatory approval.
Immune response is one of the key aspects in toxico logy studies and accumulating evidence suggests that nanoparticles can provoke immunotoxicity due to increased interaction with immune components and the use of immunostimulatory materials in nano-formulations [1, 3, 4] . Although research has suggested that physicochemical properties (size, shape, charge, surface chemistry and material composition) of nanoparticles determine their immunotoxicity [1] , no conclusive guidelines have been made for preparing low immunostimulatory nanomedicine. Studies on immunotoxicity provoked by different nanomaterials have been reviewed by others [1, 3, 4] , so instead this article focuses on comparing the immune response induced by approved therapeutic nanoparticles or nano-formulations that have been tested widely for therapeutic applications. We aim to provide a comprehensive overview on the parameters and compositions of therapeutic lipid nanoparticles that can trigger an immune response, the mechanism of inducing this reaction and how the immune response can be managed or used to enhance therapy.
The immune system is composed of innate and acquired immunity. The innate immunity system is the first line of defense against foreign organisms and can immediately respond to any stressor. It contains four different protective mechanisms: (i) a physical barrier such as skin to prevent stressors from entering; (ii) physiological response, such as increased blood flow, enhanced degradation of the stressor and activation of the immune system by regulating the temperature, pH, oxygen level or soluble factors including interferon and complement; (iii) endocytotic and phagocytotic uptake of the stressor by specialized cells; and (iv) inflammatory response that recruits immune cells (mainly macrophage and neutrophil) to help remove the stressor. The innate immune system is non-specific, has no memory and will respond similarly each time during exposure.
The adaptive immune system acts as a second line of defense and responds against re-exposure of the same pathogen. A specific antibody that recognizes the foreign pathogen is produced during the process and the response to a reexposure is rapid because a low titer of the specific antigen is already present and memory B and T cells are activated.
Immunotoxicity is defined as any adverse effect on the immune system and can be classified into five categories: (i) immunosuppression involves malfunction of any component of the immune system, leading to impaired immune response, including myelosuppression, changes in immune system organ weights and reduced serum globulin level; immunosuppression can result in increased incidence of infection; (ii) immunogenicity refers to immune reactions (often allergic response) induced by a specific stressor upon multiple exposures; and (iii) hypersensitivity is induced by a specific stressor sensitizing the immune system, leading to strong adverse reactions; (iv) autoimmune is a pathological process involving the immune system responding against self-antigens; and (v) adverse immunostimulation is caused by non-antigen-specific activation of some component in the immune system. Nanoparticles may have increased interaction with components in the immune system and provoke immune response, affecting their pharmacokinetics and the therapeutic efficacy. In the remainder of this article, we review how the innate and acquired immune systems interact with therapeutic nanoparticles, with a detailed discussion on the mechanism of the immunostimulation and the implications on the therapeutic effect. [5] demonstrated that the Taxol formulation formed micelles in the 8 -22 nm range upon dilution, followed by de novo formation of 50 -300 nm droplets in human plasma. These particles (but not the filtrate after particle removal) activated complement by increasing the levels of complement proteins (C3a-desarg, iC3b and SC5b-9) in human serum after 5 -30 min of incubation, which could be inhibited by human immunoglobulin (IVIG), an agent to treat complement activation. Taxol frequently induces hypersensitivity reactions with symptoms varying from mild pruritus to anaphylaxis [6] . Therefore, all patients must be premedicated prior to Taxol administration to prevent severe hypersensitivity reactions and Taxol needs to be slowly infused for 3 h. Such premedication consist of dexamethosone at 12 and 6 h before Taxol treatment, promethazine at 30 -60 min prior to Taxol therapy, and cimetidine or ranitidine at 30 -60 min before Taxol administration. The hypersensitivity reactions predominantly occur during the first 10 min of infusion and are usually restricted to the first two cycles. The reactions are caused by multiple factors and several mechanisms have been suggested [6] : (i) an IgE-mediated mast cell degranulation caused by paclitaxel or Cremophor EL; (ii) a non-IgE-mediated idiosyncratic mast cell degranulation induced by paclitaxel or Cremophor EL; and (iii) complement activation as discussed above.
Doxil activates complement
Doxil is an 80-nm PEGylated liposomal formulation of doxorubicin for the treatment of Kaposi ' s sarcoma, metastatic ovarian cancer and metastatic breast cancer. Doxil therapy is associated with hypersensitivity reactions with a frequency between 0 % and 25 % despite pretreatment of patients with corticosteroids and antihistamines [7] . Symptoms include facial flushing, dyspnea, tachypnea, facial swelling, headache, chills, hypotension or hypertension, chest pain and back pain. Unlike IgE-mediated allergy, these reactions occur predominantly during the first dose without prior sensitization. As standard doxorubicin does not cause hypersensitivity reactions, the lipid nanoparticle has been postulated to induce this effect. Chanan-Khan et al. [7] showed that Doxil therapy activated complement in 21 out of 29 patients (72 % ) and induced moderate to severe hypersensitivity reactions in 13 out of 29 patients (45 % ). Most of the complement activation (76 % ) occurred immediately after the infusion and was transient in nature. At 10 min after Doxil infusion, the plasma level of SC5b-9 was significantly increased in 92 % of the patients who developed hypersensitivity reactions, vs. 56 % in the group with no hypersensitivity, and the rise was higher in the hypersensitivity group than in the nonhypersensitivity group. The data and statistical analysis indicate that complement activation plays a casual role in hypersensitivity reactions caused by Doxil, although complement activation does not always lead to hypersensitivity, suggesting the involvement of yet to be identified amplification factors. The data also showed that Doxil dose and infusion rate were both positively correlated to the increased level of complement activation and risk of hypersensitivity reactions.
Inflammation and phagocytosis induced by lipid nanoparticles

Cationic lipid nanoparticles interact with immune cells and trigger immune response
Cationic liposomes are commonly used as a non-viral gene delivery system and as an immunoadjuvant for vaccines [8] . The Huang laboratory has demonstrated that s.c. injected cationic liposomes ( ∼ 100 nm) were largely taken up by dendritic cells (DCs) [9 -13] . These cationic liposomes stimulated antigen presenting DCs, leading to the expression of co-stimulatory molecules, CD80 and CD86, but not promoting the expression of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α ) [11] . This effect was not measured with zwitterionic and anionic liposomes. The cationic lipid containing ethyl phosphocholine (EPC) head groups exhibited increased immunostimulatory activity compared to their trimethylammonium propane (TAP) counterparts. For cationic lipids bearing TAP head groups, the ones that contained unsaturated or shorter hydrophobic chains exhibited enhanced activity. Yan et al. [13] reported that DC stimulation by optimal cationic liposomes composed of DOTAP (1,2-dioleyl-3-trimethylammonium propane) was mediated by reactive oxygen species (ROS), which activated extracellular signal-regulated kinase (ERK) and p38, and the downstream cytokines/chemokines, such as interleukin-12 (IL-12) and chemokine (C-C motif) ligand 2 (CCL2). Different cationic lipids could induce different immune responses via distinguished mechanisms [8] . Tanaka et al. [14] synthesized a new lipid DiC14-amidine and demonstrated that the DiC14-amidine liposomes activated the nuclear factor-κ B (NF-κ B) pathway in mouse and human DCs. They discovered that DiC14-amidine was recognized by the Toll-like receptor 4 (TLR4) and its co-receptors MD2 and CD14, inducing a cascade that led to activation of mitogen-activated protein kinases (MAPKs) and NF-κ B and expression of several proinflammatory cytokines (IL-6, IL-12, TNF-α ) and co-stimulatory molecules (CD80/ CD86) [8, 14] . Activation of TLR4 also triggered dynamindependent endocytosis [15] , which resulted in activation of interferon regulatory factor 3 (IRF-3) and expression of interferon-induced molecules (IFN-β , IP-10) [14] . These responses were not observed with other cationic lipids, including the TAP and EPC families, and dimethyldioctadecylammonium (bromide salt) (DDAB) [8, 14] .
The same cationic lipid could provoke different immune responses in different cell types. As described earlier, DOTAPliposomes did not promote proinflammatory cytokine production in DCs [8, 11, 14] . However, Kedmi and colleagues [16] reported that DOTAP-liposomes interacted with TLR4 in different subsets of leukocytes (monocytes, T cells and B cells), induced interferon type I response and elevated mRNA levels of interferon responsive genes (STAT1, OAS1, IFN-β , G1P2, MX1) 15-to 25-fold higher than neutral and negatively charged liposomes. Moreover, DOTAP-liposomes provoked a proinflammatory response by inducing Th1 cytokine expression (IL-2, IFN-γ , TNF-α ) in these cells 10-to 75-fold higher than the control particles. Intravenously injecting the DOTAP-liposomes enhanced inflammatory cytokine production (IL-2, IL-6, IL-17, IFN-γ , TNF-α ) in the splenocytes by 15-to 30-fold with increased liver damage.
Lipoplex induces systemic inflammation, which in turn reduces gene transfection
Lipoplex is the most widely studied non-viral delivery system for nucleic acids, such as pDNA, antisense oligonucleotide, small interfering RNA (siRNA) and microRNA. Lipoplex is prepared by mixing cationic liposomes with a nucleic acid and liposomes can condense nucleic acid into nano-sized particles via charge-charge interactions. Upon i.v. administration, lipoplex is mainly taken up by macrophages in the liver and the pulmonary endothelium [17] . Ten minutes after i.v. injection, approximately 35 % of the injected lipoplex was found in the liver and 35 % was detected in the lung, with < 2 % recovered in the blood and spleen [17] . In the liver, almost all of the lipoplex was cleared by Kupffer cells (macrophage in liver) [18] . Macrophage is known to phagocyte foreign particles efficiently via the endosomal/lysosomal pathway, and the lysosomal TLR-9 is exposed to nucleic acids containing a CpG motif, which in turn induces production of high levels of proinflammatory cytokines, such as TNF-α , IFNs, IL-6
and IL-12 [19] . Sellins et al. [20] demonstrated that lipoplex induced high levels of IFNs and the transfection efficiency in the lung was increased by 20-fold in IFN receptor knockout mice compared to that in wild type mice. The data suggest that the inflammation induced by lipoplex not only causes systemic toxicity but also leads to reduced gene transfection [20] . This phenomenon has been independently reported by many other groups [21 -23] .
Strategies to reduce the inflammatory toxicity of lipoplex can be summarized under three categories: (i) eliminating immunostimulatory sequences in the plasmid DNA or nucleic acids; (ii) decreasing the interaction of lipoplex with immune cells such as macrophage; (iii) suppressing the immune response to lipoplex by using immunosuppressant. Sakurai et al. [24] showed that removing CpG motifs in the plasmid DNA decreased serum levels of inflammatory cytokines (IL-6, IL-12, TNF-α ) induced by lipoplex by 10-fold. As polyethylene glycol (PEG) provides steric hindrance, PEGylation of lipoplex has been utilized to reduce the interaction between lipoplex and immune cells to reduce its inflammatory toxicity [25] . The Huang laboratory has developed the sequential injection technique, injecting cationic liposomes first, followed by pDNA 2 min later [17] . Sequential delivery resulted in > 70 % injected pDNA detected in the lung and only 5 % of the injected pDNA measured in the liver, with 2-fold reduced levels of inflammatory cytokines (TNF-α , IL-12 and IFN-γ ) and 3-to 10-fold increased gene transfection in the lung [17, 18] . They discovered that serum protein binding to the sequential complex and lipoplex was different with increased interaction of apolipoprotein A1 (apoA1), transferrin and albumin in the sequential complex, which altered the biodistribution of the complex, leading to enhanced lung uptake and reduced Kupffer cell interaction, and decreased inflammatory toxicity [18] . In addition, Liu et al. [26, 27] incorporated non-steroidal anti-inflammatory drugs (dexamethasone and prednisone) and agents that inhibit NF-κ B (capsaicin) and MAPK (PD9805) inflammatory pathways into the lipid bilayer of lipoplex, and showed that the levels of inflammatory cytokines (TNF-α , IL-12 and IFN-γ ) were reduced by 2-to 10-fold. Elouahabi et al. [22] showed that a single pre-injection of empty DiC14-amidine liposomes reduced TNF-α production by 2-to 3-fold induced by the subsequent DiC14-amidine/protamine/pDNA complex, which in turn increased the transgene expression by 40-fold. This interesting result, however, was contradictory to their earlier report indicating that the DiC14-amidine liposomes induced significant production of inflammatory cytokines, including TNF-α [14] . The underlying mechanism of the liposomes suppressing TNF-α production following i.v. administration needs to be investigated.
Research with polyplex (cationic polymer complex with nucleic acids) shows similar results, where naked polyplex induces high levels of inflammatory cytokines by delivering nucleic acids to Kupffer cells, and PEGylation could be employed to minimize inflammation [28] .
Stable nucleic acid lipid nanoparticle (SNALP) interacts with DCs and peripheral blood mononuclear cells and provokes inflammatory response
SNALP is a PEGylated lipid nanoparticle that encapsulates nucleic acids in the inner phase and is one of the first nanoparticles successfully delivering siRNA to silence target genes via systemic injection [29, 30] . PEG-lipid in the formulation is designed to rapidly diffuse out of nanoparticles when circulating in the blood, so that serum apoE can bind to the surface to interact with the low-density lipoprotein (LDL) receptor on the hepatocyte for receptor-mediated internalization [31] . This delivery system is therefore mainly used to deliver siRNA for treating liver diseases, such as liver cancer, hepatitis B and high cholesterol, and is currently in clinical trials. siRNA can be a potent trigger for immune response via TLRs in the endosome/lysosome, particularly when associated with delivery vesicles that increase intracellular uptake [19] . Judge and colleagues [32, 33] found that naked siRNA was not immunostimulatory; however, when encapsulated in SNALP, increased levels of inflammatory cytokines (IFN, TNF, IL-6) were induced and released from immune cells (DCs and peripheral blood mononuclear cells) in a dose-responsive manner. This innate immunity activating effect could lead to nonspecific anti-viral activity [34] . The team also discovered that the immunostimulatory effect of siRNA was sequencedependent and identified 5 ′ -UGUGU-3 ′ within the siRNA as an immunostimulatory motif [33] . They also showed that the sequence recognition mechanism is stringent and minimal sequence change led to significantly reduced immune response [33] . Further, immune stimulation could be completely abrogated by selective incorporation of 2 ′ -O-methyl (2 ′ -OMe) uridine or guanosine nucleosides into one strand of the siRNA duplex without disrupting gene silencing activity [32] . Interestingly, the 2 ′ -OMe-modified siRNA could act as an inhibitor of RNA-mediated inflammation via antagonizing TLR-7 [35] . Despite detailed studies in preclinical models, the ApoB-SNALP developed to treat hyperlipidemia induced significant immune response in one patient at the highest dose in the Phase I trial and the study has been terminated [36] . The underlying mechanism is under investigation.
3 Adaptive immune response against lipid nanoparticles
Repeated injections of PEGylated nanoparticles induce the accelerated blood clearance (ABC) phenomenon
The ABC phenomenon (Figure 1 ) was first reported with " empty " liposomes that did not carry any cytotoxic drug: an i.v. injection of PEGylated liposomes caused the second dose of the same liposomes to be increasingly cleared from the blood with extensive accumulation in the liver [37 -39] . It was generally believed that PEGylated liposomes composed of naturally occurring lipids and an inert PEG polymer had little immunogenicity. However, it has been demonstrated that the first dose of empty PEGylated liposomes stimulates marginal zone (MZ) B cells in the spleen, which then produce anti-PEG IgM that selectively binds to the second dose of the PEGylated liposomes, leading to substantial complement activation and reduced blood circulation of the second dose [40, 41] . Shimizu et al. [41] recently showed that these activated MZ B cells internalized the second dose of PEGylated liposomes via a PEG-dependent mechanism and transported the liposomes to the follicle region. The PEGylated liposomes given subsequently not only interacted with anti-PEG IgM but were also recognized as a T cellindependent type 2 antigen by the first line of defense against blood borne pathogens. The ABC phenomenon depends on the lipid dose, physicochemical properties of the liposomes, the time interval between injections and the encapsulated drug.
Lipid dose of the first injection
There was a significant inverse relationship between the first dose of PEGylated liposomes and the extent to which the ABC phenomenon was induced. The blood circulation half-lives (t 1/2 ) of the second dose of PEGylated liposomes were 20, 12, 10 and < 2 h when the first dose was given at 0, 5, 1 and ≤ 0.1 μ mol lipid/kg of body weight, respectively [42] . It is speculated that high dose liposomes may induce apoptosis of B cells and thus attenuate the phenomenon. liposomes with different chain lengths ( M W 2000 and 5000) were comparable [42] .
Size
Koide et al. [43] pretreated mice with PEGylated nanoparticles with different sizes (9.7, 31.5 or 50.2 nm polymeric micelles and 119, 261 and 795 nm PEGylated liposomes) and found that the ABC phenomenon only occurred to the subsequent dose of 127-nm PEGylated liposomes when the mice were initially treated was with 50.2 nm or bigger PEGylated nanoparticles. Hence, it is hypothesized that the small particles exhibit decreased interaction with the splenic B cells and thereby are less inductive in producing anti-PEG IgM compared to the big particles.
Interval between injections
Ishida et al. [44] demonstrated that the elimination t 1/2 of the second dose of PEGylated liposomes injected within 2 days after the first dose was the same as the control ( ∼ 15 h). The ABC phenomenon started to occur in 3 days (t 1/2 = 6 h), maximized in 4 -5 days (t 1/2 = 0.3 -0.5 h) and persisted for at least 2 weeks, but the effect was gradually diminished after 5 days post the first injection. The t 1/2 of the second dose of the PEGylated liposomes administered 2 weeks after the first dose was only half that of the control. This time interval effect corresponded to the plasma levels of anti-PEG IgM induced by the first dose, for which significant anti-PEG IgM levels were detected in 3 days and peaked by day 5 post the initial exposure. Another group showed that the ABC effect lasted up to 4 weeks after the first injection in rats and monkeys, and consecutive injections attenuated the effect [37] . The fourth dose injected 3 weeks after the first dose did not exhibit accelerated clearance [37] .
Encapsulated drug: cytotoxic agents
Initial studies with Doxil (PEGylated liposomal doxorubicin) showed no ABC phenomenon, although the empty PEGylated liposomal formulation induced enhanced clearance of the subsequent dose of Doxil [39] . The results suggest that the cytotoxic drug doxorubicin carried by PEGylated liposomes can suppress splenic B cell function, thereby abolishing the ABC phenomenon [40] . However, Suzuki et al. [45] recently reported that Doxil induced the ABC phenomenon in dogs in a dose-dependent manner. They discovered that when the Doxil dose was 2 Mg doxorubicin/m 2 or lower, the first dose induced elevated blood levels of anti-PEG IgM, which peaked at 5 -14 days after the injection and were still above the background when administrations of the second and the third doses were made at 21 and 42 days, respectively. This led to enhanced clearance of the second and the third dose of Doxil. Interestingly, this phenomenon was not observed with Doxil given at 20 Mg/m 2 , where blood levels of anti-PEG IgM were under the detection limit, suggesting that the inhibition of splenic B cell activation by Doxil was dose-dependent, and increased Doxil dose might deplete B cells in the spleen, thus suppressing the ABC effect [45] . It was noted that the blood level of anti-PEG IgM peaked by day 9 after the first injection and declined gradually, even with the second and the third doses. As a result, the blood clearance of the third dose was reduced compared to that of the second dose. The blood pharmacokinetics of Doxil was tightly associated with blood levels of anti-PEG IgM. Nevertheless, there has been no report of the ABC phenomenon of Doxil in human patients. La-Beck et al. [46] demonstrated that there was no significant difference in Doxil clearance in patients receiving doses between 10 and 60 Mg/m 2 of the drug. Conversely, Gabizon et al. [2] showed that Doxil clearance from the blood in patients receiving 30 -60 Mg/m 2 of Doxil was reduced by 30 % after repeated injections, which could result from depletion of the mononuclear phagocyte system (MPS).
Encapsulated drug: nucleic acids
As discussed earlier, nucleic acids can be immunostimulatory depending on their source, chemistry and sequence. When carried by PEGylated lipid nanoparticles, these immunostimulatory nucleic acids can activate splenic B cells to produce anti-PEG IgM for enhanced clearance of nanoparticles. Tagami et al. [47] demonstrated that serum levels of anti-PEG IgM were 3-to 4-fold increased in mice treated with lipoplex containing CpG-pDNA compared to that with lipoplex incorporating non-CpG-pDNA. The second dose of lipoplex containing CpG-pDNA exhibited a different profile of biodistribution compared to the first dose: the blood level of lipoplex was reduced by half (6 % vs. 3 % dose/g), the uptake by the liver and spleen was increased by 40 -60 % , and the tumor uptake was reduced by 4-fold (8 % vs. 2 % dose/g). By contrast, biodistribution profiles of the first and the second dose of lipoplex incorporating non-CpG-pDNA were comparable. They also showed that the population of the proliferative IgM + splenic cells increased from 4.04 % to 14.64 % by lipoplex containing CpG-pDNA, whereas non-CpG-lipoplex displayed mild effect (6.06 % ). These data indicate that a CpG motif in the formulation could stimulate the immune cells to promote the ABC effect against PEGylated nanoparticles. In a follow-up study, Tagami et al. [48] discovered that anti-PEG IgM inducing activity of siRNA containing PEGylated lipid nanoparticles was dependent on the siRNA sequence, and this immune response could be suppressed by introducing 2 ′ -OMe modifications to siRNA.
Diffusive PEGylated nanoparticles avoid the ABC
The ABC phenomenon was also reported with other PEGylated lipid nanoparticles containing pDNA [49] . Judge and colleagues [49] reported that stable plasmid lipid particles (SPLPs) incorporating PEG-S-DSG (a PEGylated lipid containing a C18 alkyl chain) or PEG-S-DPG (C16) increased serum levels of anti-PEG IgM, which in turn reduced gene transfection activity in the tumor by ∼ 10-fold for the second injection. However, when the acyl chain length of the PEGylated lipid was reduced to C14 (PEG-S-DMG), the resulting SPLPs only induced mild increases in serum levels of anti-PEG IgM (only 1/3 or less compared to the C16 and C18 SPLPs). As a result, gene transfection in the tumor by the second dose was comparable to that of the first dose. Additionally, no hypersensitivity reactions (scratching face, lethargy, increased respiratory rate, swelling around the eyes, cyanosis, convulsion and morbidity) were observed with mice treated with C14-SPLP, whereas mild to moderate reactions were detected for mice treated with C16 and C18-SPLP. It is speculated that C14 PEG-lipid rapidly diffuses out of the SPLPs after i.v. injection, so that the immune cells (splenic B cells) are not activated against PEG. However, when the acyl chain length is C16 or higher, the PEG-lipids stay with the SPLPs for an extended period of time in the blood circulation, which then interact with the immune cells and activate them to produce anti-PEG IgM.
C225-immunoliposomes induce specific antibodies to accelerate clearance of subsequent doses
Immunoliposomes are prepared by attaching an antibody onto a liposomal surface, so that they can target a specific cell by recognizing the corresponding antigen on the cell surface. This technology has been widely used for targeted delivery of drugs [50] . However, the immunogenicity of immunoliposomes has been the major issue of this technology. Harding et al. [51] produced immunoliposomes by linking mouse anti-human epidermal growth factor receptor IgG (C225) onto a liposomal nanoparticle, and demonstrated that antigen-binding activity of immunoliposomes was preserved and immunoliposomes exhibited long circulation times in rats [mean residence time (MRT) = 8.5 h, clearance (Cl) = 0.2 Ml/h]. However, the subsequent injections of immunoliposomes into the same animals resulted in increased clearance (MRT ≤ 0.7 h; Cl ≥ 7 Ml/h), which was accompanied by a significant increase in anti-C225 specific titers. This specific immune response was triggered by the constant human region of C225. Repeated injection or co-injection of the parent liposomes and the free C225 antibody did not increase the anti-C225 titer and the C225 displayed prolonged pharmacokinetics. However, the C225 antibody was cleared rapidly in rats that had received immunoliposomes.
The data indicate that surface coating of an antibody onto a lipid nanoparticle significantly enhances the immunogenicity of the antibody, resulting in increased anti-antibody titers and accelerated clearance of the subsequent antibody and the immunoliposomes. This immune response could cause severe hypersensitivity reactions in animals. Employment of humanized antibody or small fragments of antibody such as Fab (fragment, antigen binding region) and single chain fragment variable (scFv) has been suggested to reduce immunogenicity of the resulting immunoliposomes [50] .
Antibodies against liposomal phospholipids
Wassef and colleagues and Alving and colleagues [52 -56] reported that injecting liposomes containing an immunoadjuvant, lipid A, into mice or rabbits produced polyclonal or monoclonal antibodies against the liposomal phospholipids (anti-phosphatidylcholine and anti-phosphatidylethanolamine). However, it is believed that these low titers of antibodies will not cause autoimmune diseases, as in the diseases antibodies are against anionic phospholipids such as cardiolipin and phosphatidylinositol [57] . Liposomes without lipid A did not induce immune response against liposomal phospholipids and the role of lipid A has yet to be delineated. In the absence of lipid A, antibodies against phospholipids could only be generated in mice when injected phospholipids were in a hexagonal phase, which is a non-bilayer lipid phase [58] .
Guidelines for evaluating immunotoxicity of nanoparticles
As nanotechnology-based products are usually regarded as new chemical entities (NCEs), the NCE guidelines are usually applied for assessing immunotoxicity of nanomedicine [1] . Unfortunately, there is still no universal guide for immunotoxicity evaluation [1] . The US FDA and the Japanese guidelines recommend immune function tests in subchronic rodent models only when previous evidence indicates a need, whereas the European authorities mandate such studies as an initial screen for immunotoxicity [1] . Federal agencies are now collaborating with academia and industry to identify critical parameters in nanoparticle characterization and to establish criteria for nanotechnology-specific assays. The Nanotechnolo gy Characterization Laboratory (NCL) at the US National Cancer Institute lists several in vitro and in vivo immunological tests to evaluate immunotoxicity of nanoparticles (Table 1 ) in accordance with the published literature [3, 4, 8, 59 -63] . These include blood contact properties, immune cell-based assays and in vivo immunotoxicity evaluation. The majority of the standard immunological tests are applicable to nanoparticles; however, as pointed out by Dobrovolskaia and McNeil [1] , many nanoparticles contain materials and excipients that can interfere with the tests. For example, nanomaterials often absorb UV-VIS or fluorescence, affecting the read-outs of assays. Optimization of these methods to accurately assess the immunotoxicity of each unique nanoparticle may be required.
Summary and perspectives
It has been demonstrated that nanoparticles could exhibit increased interaction with immune components and induce undesirable immune responses via a number of different mechanisms, including complement activation, inflammatory cytokine overproduction and acquired immunity against a specific composition in the nanoparticle upon multiple exposures. These responses can lead to hypersensitivity reactions, inflammatory toxicity and accelerated clearance of subsequent doses, which in turn reduce therapeutic efficacy and increase toxicity. From the lessons learned with these lipid nanoparticles, it is well demonstrated that an enhanced understanding of all nanoparticle compositions is required to address their immunotoxicity. For example, Cremophor EL forms micelles to deliver water insoluble paclitaxel and is responsible for hypersensitivity reactions caused by Taxol. In the Nab-paclitaxel (Abraxane) formulation, human serum albumin is used to carry paclitaxel instead, and the severe immune response is thus greatly reduced. As a result, Nab-paclitaxel can be safely administered at an elevated dose for improved efficacy. CpG containing pDNA and certain siRNA sequences promote inflammatory toxicity Table 1 Immunological assays for nanotechnology-based products suggested by the Nanotechnology Characterization Laboratory. In certain cases, immunostimulatory activity of nanoparticles could be advantageous, especially for vaccine delivery [64, 65] . For example, Chen et al. [9, 10] utilized DOTAP-liposomes to deliver a peptide antigen derived from E7 oncoprotein of human papillomavirus (HPV) type 16 for development of a therapeutic vaccine against human cervical cancer. They found that the E7 peptide formulated with DOTAP-liposomes induced migration of activated DCs to the draining lymph node and efficiently generated functional antigen-specific CD8 + T lymphocyte responses, which infiltrated into the tumor and regressed the tumor with one injection at the optimal dose.
In vitro In vivo
It is emphasized that the immune response triggered by a candidate nanoparticle should be screened as early as possible during preclinical development following guidelines and protocols (Table 1) of the NCL, who also sponsors characterizing innovative nanoparticle candidates from industry and academia. Each component in nanoparticles may have its unique immunostimulatory activity and mechanism, which requires step-by-step analyses to elucidate how nanoparticles induce immunotoxicity. If a component is identified as highly immunostimulatory, a substitution of the material may be necessary. For example, Chono et al. [66] replaced calf thymus DNA in PEGylated lipid-polycation-DNA (LPD) nanoparticles with hyaluronan and developed lipid-polycation-hyaluronan (LPH) nanoparticles for siRNA delivery. Calf thymus DNA was used as a carrier DNA in LPD nanoparticles to provide improved encapsulation for siRNA, but introduced increased inflammatory toxicity. Hyaluronan is a naturally occurring and negatively charged polysaccharide, which could be collapsed into nanoparticles by polycation and cationic lipids to form LPH nanoparticles with similar chemicophysical properties as LPD nanoparticles. They showed that LPH nanoparticles displayed similar gene silencing activity, whereas immunotoxicity was reduced compared to LPD nanoparticles, with a > 3-fold increased therapeutic window.
Immunotoxicity of nanoparticles is still an understudied field and predicting immunotoxicity of a nanoparticle with certain chemicophysical parameters is still not possible. A general trend has been observed that nanoparticles with a small size ( < 50 nm), neutral and hydrophilic surface are usually less interactive with the immune system and thus less immunogenic [1] . However, this phenomenon strongly depends on the materials and compositions in the particles. A systemic study with controlled variables and parameters of nanoparticles is warranted to draw solid conclusions. For example, to study the size effect of a lipid nanoparticle on the immune response, lipid nanoparticles with the same compositions but in different sizes should be prepared and tested. Unfortunately, making different particles by changing only one variable is not always possible.
As an increasing number of nanotechnology-based products are failing early clinical trials due to unexpected immune responses, characterization of immunotoxicity for nanoparticle candidates is becoming important in preclinical toxicology screening. Screening often starts with blood compatibility (hemolysis, coagulation), sterility, endotoxin and complement activation. Immunological tests can be incorporated into regular animal toxicology studies, including immune organ weight, histopathology examining tissue infiltration of immune cells and plasma levels of cytokines and chemokines. It is worth mentioning Bio-Plex Pro ™ magnetic beads technology (Bio-Rad), which allows measurement of a panel of 23 cytokines in a sample in one well of a microplate, representing a more economical approach to efficiently screen cytokine activation than conventional ELISA methods.
Finally, the underlying mechanism of immunotoxicity of a nanoparticle should be delineated and the results should be published to contribute knowledge to this field. Cumulative data will lead to an enhanced understanding of how the immune system interacts with nanoparticles, what materials are immunogenic and what strategies can be used to reduce the immune response. 
